David Hupin1, Frédéric Roche2, Vincent Gremeaux3, Jean-Claude Chatard4, Mathieu Oriol5, Jean-Michel Gaspoz6, Jean-Claude Barthélémy2, Pascal Edouard4. 1. Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, PRES Lyon, Jean Monnet University, Saint-Etienne, France EA SNA EPIS 4607, Autonomic Nervous System, University of Lyon, Saint-Etienne, France EA LPE 4338, Laboratory of Exercise Physiology, University of Lyon, Saint Etienne, France. 2. Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, PRES Lyon, Jean Monnet University, Saint-Etienne, France EA SNA EPIS 4607, Autonomic Nervous System, University of Lyon, Saint-Etienne, France. 3. Rehabilitation Departments, University Hospital of Dijon, Dijon, France Faculty of Sport Sciences, INSERM-U1093, University of Burgundy, Dijon, France CIC INSERM 1432, Technological Platform, University Hospital of Dijon, Dijon, France. 4. Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, PRES Lyon, Jean Monnet University, Saint-Etienne, France EA LPE 4338, Laboratory of Exercise Physiology, University of Lyon, Saint Etienne, France. 5. Department of Public Health, Hygee Centre, Regional Centre for Cancer Prevention, Saint-Priest-en-Jarez, France CIC 1408 INSERM, Jean Monnet University, Saint-Etienne, France. 6. Division of Primary Care Medicine, Department of Community Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
Abstract
BACKGROUND: The health benefits of 150 min a week of moderate-to-vigorous-intensity physical activity (MVPA) in older adults, as currently recommended, are well established, but the suggested dose in older adults is often not reached. OBJECTIVES: We aimed to determine whether a lower dose of MVPA was effective in reducing mortality, in participants older than 60 years. METHODS: The PubMed and Embase databases were searched from inception to February 2015. Only prospective cohorts were included. Risk ratios of death were established into four doses based on weekly Metabolic Equivalent of Task (MET)-minutes, defined as inactive (reference), low (1-499), medium (500-999) or high (≥1000). Data were pooled and analysed through a random effects model using comprehensive meta-analysis software. RESULTS: Of the 835 reports screened, nine cohort studies remained, totalling 122 417 participants, with a mean follow-up of 9.8±2.7 years and 18 122 reported deaths (14.8%). A low dose of MVPA resulted in a 22% reduction in mortality risk (RR=0.78 (95% CI 0.71 to 0.87) p<0.0001). MVPA beyond this threshold brought further benefits, reaching a 28% reduction in all-cause mortality in older adults who followed the current recommendations (RR=0.72 (95% CI 0.65 to 0.80) p<0.0001) and a 35% reduction beyond 1000 MET-min per week (RR=0.65 (95% CI 0.61 to 0.70) p<0.0001). CONCLUSIONS: A dose of MVPA below current recommendations reduced mortality by 22% in older adults. A further increase in physical activity dose improved these benefits in a linear fashion. Older adults should be encouraged to include even low doses of MVPA in their daily lives. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: The health benefits of 150 min a week of moderate-to-vigorous-intensity physical activity (MVPA) in older adults, as currently recommended, are well established, but the suggested dose in older adults is often not reached. OBJECTIVES: We aimed to determine whether a lower dose of MVPA was effective in reducing mortality, in participants older than 60 years. METHODS: The PubMed and Embase databases were searched from inception to February 2015. Only prospective cohorts were included. Risk ratios of death were established into four doses based on weekly Metabolic Equivalent of Task (MET)-minutes, defined as inactive (reference), low (1-499), medium (500-999) or high (≥1000). Data were pooled and analysed through a random effects model using comprehensive meta-analysis software. RESULTS: Of the 835 reports screened, nine cohort studies remained, totalling 122 417 participants, with a mean follow-up of 9.8±2.7 years and 18 122 reported deaths (14.8%). A low dose of MVPA resulted in a 22% reduction in mortality risk (RR=0.78 (95% CI 0.71 to 0.87) p<0.0001). MVPA beyond this threshold brought further benefits, reaching a 28% reduction in all-cause mortality in older adults who followed the current recommendations (RR=0.72 (95% CI 0.65 to 0.80) p<0.0001) and a 35% reduction beyond 1000 MET-min per week (RR=0.65 (95% CI 0.61 to 0.70) p<0.0001). CONCLUSIONS: A dose of MVPA below current recommendations reduced mortality by 22% in older adults. A further increase in physical activity dose improved these benefits in a linear fashion. Older adults should be encouraged to include even low doses of MVPA in their daily lives. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Elderly people; Health promotion; Meta-analysis; Physical activity; Public health
Authors: Christine Miaskowski; Melisa L Wong; Bruce A Cooper; Judy Mastick; Steven M Paul; Katherine Possin; Michael Steinman; Janine Cataldo; Laura B Dunn; Christine Ritchie Journal: J Pain Symptom Manage Date: 2017-07-15 Impact factor: 3.612
Authors: Danilo Iannetta; Daniel A Keir; Federico Y Fontana; Erin Calaine Inglis; Anmol T Mattu; Donald H Paterson; Silvia Pogliaghi; Juan M Murias Journal: Sports Med Date: 2021-04-26 Impact factor: 11.136
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690